Welcome to the 2022 Stanford Drug Discovery Symposium

This symposium provides a valuable and important platform for inspiring interdisciplinary exchange at the forefront of drug research and will support a fantastic networking experience. It provides a great resource for researchers, pharmaceutical companies, investment groups, and those in the wider biomedical community interested in discovering new drugs and improving patient care. We look forward to an exciting two days of talks and discussion.

Joseph C. Wu, MD, PhD
Director, Cardiovascular Institute

Participant Interaction Platform

SDDS will be using Slido as a platform to send questions to the speakers. Please note that the speakers may not have time to answer all questions during the panel sessions.

Slido is accessible using the following formats:

Webpage: Simply type your question in the Slido interface on the viewing webpage.

New browser window: Open the Slido website in a new browser window and enter participant code #SDDS2022 in the "Joining as a Participant" field at the top of the page.

Cellphone: You can use Slido on your mobile phone (no app download required). Just scan the QR code below.

REGISTRATION
tinyurl.com/SDDS2022

DAY-OF VIEWING PAGE
tinyurl.com/SDDS2022-livestream

SOCIAL MEDIA
#SDDS2022
Monday, April 25

Time (PDT) | WELCOME TO DAY 1
---|---
9:00 am | Joseph C. Wu, MD, PhD
Director, Stanford Cardiovascular Institute
Simon H. Stertzer, MD, Professor of Medicine and Radiology

9:05 am | Lloyd Minor, MD
Dean, Stanford School of Medicine

9:10 am | Marc Tessier-Lavigne, PhD
President, Stanford University

SESSION I: PRESENTATION OF LIFETIME ACHIEVEMENT AWARD
Moderator: Randy Schekman, PhD; Co-Moderator: Joseph C. Wu, MD, PhD

9:15 am | Introduction of Katalin Karikó, PhD
Randy Schekman, PhD
Professor of Molecular and Cell Biology, University of California, Berkeley; 2013 Nobel Laureate

9:20 am | AWARDEE LECTURE: Katalin Karikó, PhD
Senior Vice President, BioNTech
Developing mRNA for therapy

9:40 am | Question & Answer

9:55 am | BREAK

SESSION II: RESEARCH DEVELOPMENT I
Moderator: Myrtle Davis, DVM, PhD; Co-Moderator: Mark Mercola, PhD

10:05 am | Claude Bertrand, PhD
Executive Vice President R&D, Chief Scientific Officer, Servier
Servier: A New Paradigm for R&D through a significant Transformation Journey

10:18 am | Dean Li, MD, PhD
Executive VP and President of Merck Research Laboratories
The Balance of Computing Power and Human Intelligence

10:30 am | Ray Deshaies, PhD
Sr. Vice President, Global Research, Amgen
Multispecific Molecular Medicines

10:43 am | Carlos O. Garner, PhD
Vice President, Global Regulatory Affairs, Eli Lilly and Company
How COVID Will Reshape Clinical Research

10:57 am | Panel Discussion

11:20 am | BREAK

SESSION III: PATENT LAW
Moderators: Karin Immergluck, PhD; Co-Moderator: Kuldev Singh, MD

11:20 am | Madhuri Roy, JD, PhD
Partner, Patent Counseling & Prosecution, Cooley
Getting your IP House In Order
Monday, April 25

SESSION III: PATENT LAW Con’t
Moderators: Karin Immergluck, PhD; Co-Moderator: Kuldev Singh, MD

11:33 am  Vern Norviel, JD
Partner, Patents and Innovations, Wilson Sonsini
Drug Label Patent Extension

11:46 am  Hogene Choi, JD
Partner, Morrison & Foerster
Strategies for Protecting Software Innovation in Drug Discovery

12:00 pm  Panel Discussion

SESSION IV: PUBLIC POLICY
Moderators: Steven Artandi, MD, PhD; Co-Moderator: Mark Mercola, PhD

12:45 pm  Michelle McMurry-Heath, MD
President & Chief Executive Officer, Biotechnology Innovation Organization
The Distribution of Scientific Progress: The Social Justice Issue of our Age

1:00 pm  Gary Gibbons, MD
Director, NHLBI
Accelerating the Cycle of Innovation for Drug Discovery to Prevent and Preempt Chronic Disease

1:16 am  Jacqueline Corrigan-Curay, JD, MD
Principal Deputy Center Director, FDA, CDER
Evidence Generation – Enhancing Access and Equity

1:29 pm  Maria Millan, MD
President and Chief Executive Officer, CIRM
CIRM: Building California’s Public-Private Partnerships to Accelerate the Development of Genes and Therapies

1:47 pm  Panel Discussion

2:05 pm  BREAK

SESSION V: RESEARCH DEVELOPMENT II
Moderator: Sandra Horning, MD; Co-Moderator: Sanjay Malhotra, PhD

2:10 pm  Alfred Sandrock, MD, PhD
CEO, Voyager Therapeutics
The Discovery and Development of Aducanumab for Alzheimer’s Disease

2:30 pm  Lisa Coussens, PhD
President, AACR; Associate Director for Basic Research, Knight Cancer Institute, Oregon Health & Science University
Neutralizing Protumor Inflammation: Lessons Learned from Preclinical Mouse Models

2:47 pm  Randy Schekman, PhD
Professor of Molecular and Cell Biology, University of California, Berkeley; 2013 Nobel Laureate
Engineering a Membrane-Mediated Delivery of Genome Editing Functions

2:59 pm  Panel Discussion

3:20 pm  Joseph Wu, MD, PhD
Day 1 Closing Remarks
Tuesday, April 26

Time (PDT)  WELCOME TO DAY 2
9:00 am  Joseph Wu, MD, PhD
Director, Stanford Cardiovascular Institute
Simon H. Stertzer, MD, Professor of Medicine and Radiology

SESSION VI: RESEARCH DEVELOPMENT III
Moderators: Kathleen Giacomini, PhD; Co-Moderator: Kuldev Singh, MD
9:05 am  Aida Habtezion, MD
Chief Medical Officer and Head of Worldwide Medical & Safety, Pfizer
Translating Lessons from the Covid-19 Programs
9:22 am  Mathai Mammen, MD, PhD
Executive Vice President, Pharmaceuticals, R&D, Johnson & Johnson
Raising the Bar for Innovation
9:42 am  Peter Marks, MD, PhD
Director, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration
Facilitating the Development and Manufacturing of COVID-19 Vaccines
9:52 am  Panel Discussion
10:10 am  BREAK

SESSION VII: FIRESIDE CHAT WITH KATALIN KARIKÓ, PHD
Moderator: Dean Lloyd Minor, MD; Co-Moderator: Sanjay Malhotra, PhD
10:20 am  Katalin Karikó, PhD
Senior Vice President, BioNTech
Lloyd Minor, MD
Dean, Stanford School of Medicine

Time (PDT)  SESSION VIII: INVESTING IN DISCOVERY
Moderators: Amy L. Chang, MSEE; Co-Moderator: Sanjay Malhotra, PhD
10:50 am  Joe Jimenez, MBA
Aditum Ventures
The Evolving Role of Venture Capital in the Pharma Ecosystem
11:01 am  David Goel
Founder & Managing General Partner, Matrix Capital Management
The Convergence of Technology and the Life Sciences
11:22 am  Jonathan MacQuitty, PhD
Sector Head for Life Sciences, Lightspeed Ventures
A New Approach to Healthcare Investing
11:36 am  Margarita Chavez, JD
Managing Director, AbbVie Ventures
11:46 am  Panel Discussion
12:05 pm  BREAK
SESSION IX: ARTIFICIAL INTELLIGENCE TECHNOLOGIES
Moderators: James Zou, PhD; Co-Moderator: Mark Mercola, PhD

12:35 pm Christopher Gibson, PhD
Co-Founder, Chief Executive Officer, Recursion
Mapping and Navigating Biology at Scale

12:48 pm Daphne Koller, PhD
Founder & Chief Executive Officer, Insitro
Transforming Drug Discovery using Digital Biology

1:00 pm Karen Akinsanya, PhD
President, R&D Therapeutics, Schrödinger
Transitioning from Computer-aided and Empirical Drug Discovery to Computer-driven and Structure-based Drug Discovery

1:14 pm Panel Discussion

1:35 pm BREAK

SESSION X: RESEARCH DEVELOPMENT IV
Moderator: Peter Kim, PhD; Co-Moderator: Kuldev Singh, MD

1:45 pm Andrew Plump, MD, PhD
President, Research & Development, Takeda Pharmaceutical
Creating a Patient-Drive, Science-First R&D Organization

1:58 pm Aviv Regev, PhD
Executive Vice President, Research and Early Development, Genentech
Multiplicative Levers for Drug Discovery and Early Development

2:13 pm James Bradner, MD
President, Novartis Institutes of BioMedical Research
New Paradigms in Therapeutics

2:29 pm Merdad Parsey, MD, PhD
Chief Medical Officer, Gilead
Development of Treatments for the Globe: from HIV to COVID-19

2:41 pm Panel Discussion

3:00 pm Joseph Wu, MD, PhD
Day 2 Closing Remarks
Katalin Karikó is Senior Vice President of BioNTech SE, Professor of University of Szeged, and Adjunct Professor of Neurosurgery, Perelman School of Medicine, University of Pennsylvania. Dr. Karikó graduated from University of Szeged, Hungary in 1978, and received a doctoral degree in biochemistry from the same university in 1982. She continued her research at the Biological Research Centre in Szeged, at the Temple University in Philadelphia and at the Medical School of the University of Pennsylvania where she worked for 24 years. From 2013, Karikó is a senior vice president at BioNTech located in Mainz, Germany, where she is leading the mRNA-based protein replacement programs. For four decades, her research has been focusing on RNA-mediated mechanisms with the ultimate goal of developing in vitro-transcribed mRNA to treat acquired and genetic diseases. She was perfecting the therapeutic mRNA for years, and in 1997, joined forces with Drew Weissman and together they made mRNA suitable for medical use by replacing the uridine with pseudouridine, thus making the mRNA noninflammatory. They—together with their team—further demonstrated that such modified mRNA formulated with LNP can be a potent vaccine. This technology ultimately became the basis for the FDA approved COVID-19 mRNA vaccine that is used to combat the current global pandemic. Their pioneering work fueled a number of advances and has opened the door for future therapeutics. Karikó has received prestigious awards, including the Széchenyi Prize, Rosenstiel Award, Reichstein Medal, Horwitz Prize, Breakthrough Prize and Lasker Award.
Karen Akinsanya, PhD

Karen Akinsanya, President of R&D, Therapeutics, joined Schrödinger in 2018. Karen leads the company’s therapeutics group which is responsible for preclinical drug discovery, translational research, and early clinical development, in addition to drug discovery business development and collaborations. She has more than 25 years of experience in academia, pharmaceutical R&D, partnerships, and licensing. Karen joined Merck Research Labs in 2005 and held positions of increasing responsibility in clinical pharmacology as a development team leader working on first-in-human studies through late-stage label studies before joining Discovery Preclinical & Early Development as a therapeutic area lead and then a search and evaluation lead in business development. Karen received her Ph.D. from the Royal Postgraduate Medical School at Imperial College in London, in endocrine physiology. Dr. Akinsanya is currently a member of the Board of Directors at Nautilus Biotechnology, Board of Directors of the Imperial College Foundation, the Board of Trustees of The Rockefeller University, the Scientific Advisory Boards of Variant Bio and Thermo Fisher Scientific.

Steven Artandi, MD, PhD

Steven Artandi, MD, PhD is the Laurie Kraus Lacob Director of the Stanford Cancer Institute and the Jerome and Daisy Low Gilbert Professor of Medicine and Biochemistry at Stanford University. He also serves as the inaugural Senior Associate Dean for Cancer Programs for Stanford School of Medicine and the Chief Cancer Officer for Stanford Health Care. He received his undergraduate degree from Princeton University, and MD and PhD degrees from Columbia University. He trained in Internal Medicine at Massachusetts General Hospital and in Oncology at Dana-Farber Cancer Institute before joining the Stanford faculty in 2000. Dr. Artandi is an oncologist and cancer biologist whose research work has focused on the role played by the enzyme telomerase in cancer, aging and stem cell function. His work has produced new insights into the origins of cancer, revealing how telomerase endows cells with immortal growth properties and how aspiring cancers circumvent critical bottlenecks encountered during carcinogenesis. He has received a number of awards including an Outstanding Investigator Award from the National Cancer Institute and is an elected member of the American Association for the Advancement of Science, the American Society for Clinical Investigation and the Association of American Physicians. He serves on the Editorial Boards of the journals Molecular Cancer Research and Stem Cells.

Claude Bertrand, PhD

Dr. Claude Bertrand graduated in pharmacy (PharmD) from Strasbourg University, France, and obtained his PhD in Strasbourg with research in the fields of immunopharmacology and neurogenic inflammation. After a 2-year post-doctoral appointment at University of California, San Francisco, Claude joined the allergy and asthma unit at Ciba-Geigy (later Novartis) in Basel. In 1996, he moved to the Inflammatory disease Unit at Roche Bioscience in Palo Alto, CA, where he became head of the in vivo pharmacology group and was responsible for supporting projects in rhumatology and respiratory diseases. In 1999, he was recruited as Director of Biology for Inflammation, GI and Pain at Pfizer. In 2004, Dr. Bertrand joined AstraZeneca as Vice-President Discovery for Respiratory & Inflammation Research at Alderley Park, UK and in 2005 was appointed Global Senior Vice President for Respiratory & Inflammation Research Area overseeing R&D activities at three sites in the UK and Sweden. In 2009, Dr. Bertrand joined Ipsen, France, as Executive Vice-President, Chief Scientific Officer and was since June 2011, Executive Vice-President for Research & Development, Chief Scientific Officer with a focus on Oncology, Neurology and Endocrinology. In March 2017, Claude was appointed General Director R&D, Chief Scientific Officer at Servier and then promoted to EVP R&D joining the EXCOM on November 1, 2018. Claude sits on at the Board of Directors of Eclosion2, MAAT Pharma and he is Advisor to Abivax Board.
James Bradner, MD
James Bradner, M.D., joined Novartis on January 1, 2016 and became President of the Novartis Institutes for BioMedical Research (NIBR) on March 1, 2016. He is a member of the Executive Committee of Novartis. Prior to joining Novartis, Dr. Bradner was on the faculty of Harvard Medical School in the Department of Medical Oncology at the Dana-Farber Cancer Institute in the United States from 2005 through 2015. Dr. Bradner is a co-founder of five biotechnology companies and has authored more than 250 scientific publications and 50 US patent applications. Dr. Bradner is a graduate of Harvard University and the University of Chicago Medical School in the US. He completed his residency in medicine at Brigham and Women's Hospital and his fellowship in medical oncology and hematology at the Dana-Farber Cancer Institute. He has been honored with many awards and was elected into the American Society for Clinical Investigation in 2011 and the Alpha Omega Alpha Honor Medical Society in 2013.

Amy Chang, MSEE
Amy Chang, MSEE
Amy serves on the board of directors for Disney, Procter & Gamble, Marqeta, SambaNova, Pragma and has previously served on the boards of Cisco, Splunk and Informatica, which encompass nearly a trillion dollars in total market cap. Post-acquisition of her startup Accompany by Cisco for $270M, she led Cisco’s multi-billion dollar Collaboration business. As EVP and GM of this 6000 person team, she led the videoconferencing, cloud calling, contact center, video device and phones businesses. Accompany was an AI/ML-based relationship intelligence platform serving Fortune 500 companies.

Prior to Accompany, Amy was at Google, where she led the teams for Google Analytics, Website Optimizer, Trends, and multichannel attribution for over 7 years, growing Google Analytics to serve over 86% of the entire web. She previously led product for the paid search and affiliates channels at eBay, as well as worked in the semiconductor and software industries at McKinsey. She started her career in hardware with Intel, AMD and Motorola.

She serves on the UCSF Hospital Executive Committee, the Stanford School of Engineering Dean's Advisory Board, and as an advisor to Panther Labs, DataRobot, Greenlight, DataChat, Snorkel.ai, PerfectDay, KatanaGraph, Galileo, Prosimo.io, NoviConnect, Hubspot (now public), Datorama (acquired by Salesforce), Skyhigh Networks (acquired by McAfee), Optimizely (acquired by Episerver), BloomReach, Origami Logic (acquired by Intuit).

Amy holds a BS in Electrical Engineering with a hardware subspecialty and an MS in Electrical Engineering with a network systems subspecialty, both from Stanford University.

Margarita Chavez, JD
Margarita Chavez, JD
Margarita is Managing Director at AbbVie Ventures. Margarita has lead investments in over a dozen biotech companies in the US and Europe and is responsible for AbbVie's investments in Morphic Therapeutics, Palleon Pharmaceuticals, eFFCTOR Therapeutics, CARISMA Therapeutics, Jnana Therapeutics and Paragen Bio. Margarita brings over 20 years of dealmaking experience, with over a decade in biotech M&A, licensing, and venture. Most recently, Margarita was a Director with Abbott's Global Pharmaceutical Licensing & Acquisitions. Among other deals, Margarita was involved in the in-licensing of Elagolix, the acquisition of Immuvem, and the acquisition of the Lupron franchise. Before joining Abbott, Margarita practiced as a corporate and securities lawyer in Silicon Valley with the firm of Brobeck Pfleger & Harrison, advising in equity financings, M&A and IPOs. Margarita currently serves as a Board Member of the New England Venture Capital Association and the MidAmerica Healthcare Investors Network and on the Advisory Board of the Santa Clara University School of Law.
Jacqueline Corrigan-Curay, JD, MD

Jacqueline Corrigan-Curay, JD, MD, is the Principal Deputy Center Director in FDA’s Center for Drug Evaluation and Research (CDER). Most recently, she served as the Acting Center Deputy Director for Operations, directing center and agency-level priority and initiative programs and leading GDUFA III reauthorization negotiations. Previously, Dr. Corrigan-Curay was director of CDER’s Office of Medical Policy (OMP). In that role, she led the development, coordination, and implementation of medical policy programs and strategic initiatives. Dr. Corrigan-Curay brings to the position a unique legal, scientific policy, and clinical background with expertise in risk and scientific assessment, and clinical trial design and oversight. Before joining FDA, she served as supervisory medical officer with the Immediate Office of the Director, National Heart, Lung and Blood Institute (NHLBI) at the National Institutes of Health (NIH). She also served in director and acting director roles with the Office of Biotechnology Activities (OBA), Office of Science Policy at NIH, where she was executive secretary of the NIH Recombinant DNA Advisory Committee. She has held positions as an attending physician with the VA Medical Center, a policy analyst with the Congressional Office of Technology Assessment, and as a practicing attorney in Washington, D.C. Dr. Corrigan-Curay earned her law degree from Harvard Law School, her medical degree from University of Maryland School of Medicine, and a bachelor’s degree in history of science from Harvard/Radcliffe College in Cambridge, MA.

Hogene Choi, JD

Hogene Choi works with clients at the forefront of the life sciences, healthcare, and technology industries on a range of intellectual property matters, focusing on patent prosecution, transactions, and counseling.

She works closely with her clients to understand their business objectives and develop strategies to protect and defend their intellectual property throughout the product life cycle. Her patent prosecution and transaction experience covers technologies related to machine learning and artificial intelligence, bioinformatics, blockchain, computer vision, cloud infrastructure and services, internet applications and server-side architecture, desktop applications and operating systems, graphics and audio/video, as well as semiconductors, medical devices, electronics, nanotechnology, and the mechanical arts. She also has extensive due diligence experience and regularly advises clients on patent procurement transactions, licensing, and acquisitions. She provides counsel on patentability and freedom-to-operate issues as well as patent portfolio evaluations for business transactions.

Hogene received her B.A. in computer science from University of California, Berkeley and her J.D. from University of California, Hastings College of the Law.
Lisa M. Coussens, PhD

Dr. Coussens is Chairwoman of the Department of Cell, Developmental & Cancer Biology, and Associate Director for Basic Research in the Knight Cancer Institute at Oregon Health & Sciences University, and holds the Hildegard Lamfrom Endowed Chair in Basic Science. Dr. Coussens’s research focuses on dissecting the roles of normal immune cells in regulating various facets of solid tumor development, identifying leukocyte activities that are co-opted by early tumors to support ongoing cancer development, and in understanding the role leukocytes play in regulating responses to cytotoxic, targeted and immune-based therapies. Her research has identified critical immune-regulated pathways for therapeutic targeting that are being clinically translated in combination with chemotherapy in women with metastatic triple negative breast cancer, pancreas cancer, and head & neck squamous cancer. In recognition of her research contributions Dr. Coussens’ has been acknowledged with multiple awards in recognition of her scientific contributions including the 13th Rosalind E. Franklin Award from the National Cancer Institute (2015), the 12th AACR-Princess Takamatsu Memorial Lectureship (2018), the 2018 Susan G. Komen Brinker Award for Scientific Distinction in Basic Science, and was elected as Fellow of the American Association for Advancement of Science (AAAS; 2018) and Fellow of the AACR Academy (2019), and most recently elected as AACR President-elect (2021) and President (2022).

Myrtle Davis, DVM, PHD

Dr. Myrtle Davis is the Vice President of Discovery Toxicology at Bristol Myers Squibb. Myrtle joined BMS from the National Cancer Institute where she was the Chief of the Toxicology and Pharmacology Branch of the Developmental Therapeutics Program. Myrtle has previous experience as a Research Advisor in the Drug Safety group of Lilly Research Laboratories. In both roles, she contributed critical expertise to the advancement of several drugs candidates and to the understanding of toxicological mechanisms. She also has several years of academic experience as an Associate Professor in the Department of Pathology in the School of Medicine at the University of Maryland.

Myrtle is currently responsible for leading the scientific efforts in Discovery Toxicology to provide target and molecular hazard identification and risk assessments for issues identified in discovery research. She also leads and oversees the investigative toxicology efforts needed to support mechanistic understanding of compound- or target-mediated toxicities in discovery and development.

Myrtle is a Fellow of the Academy of Toxicological Sciences, an active member of the Society of Toxicology (recently elected as Vice President elect for the Society), and a member of the Society of Toxicologic Pathology. She is currently serving on the Board of Scientific Councilors of the National Toxicology Program, and she is a reviewer for the Assay Development and Screening Technologies Laboratory of the National Center for Advancing Translational Sciences (NCATS). She is an Associate Editor for Toxicological Sciences and Toxicologic Pathology, and she is Editor-in-Chief of the ILAR Journal (Institute for Laboratory Animal Research of the National Academy of Sciences).

Myrtle attended Tuskegee University where she pursued a BS degree in Chemistry and Mathematics followed by a Doctorate of Veterinary Medicine. She then received her Ph.D. in Toxicology from the University of Illinois and obtained post-doctoral training in Toxicologic Pathology at the University of Maryland before starting her academic career.
Ray Deshaies, PhD

Prior to joining Amgen, Deshaies served as a professor at the California Institute of Technology (Caltech) and an executive officer in Caltech's Division of Biology and Biological Engineering. He was also an investigator at the Howard Hughes Medical Institute. He has published over 150 papers on various subjects including discoveries of Sec61 translocon, cullin–RING ubiquitin ligases, and proteolysis-targeting chimeric molecules (Protacs). In addition to his academic work, Deshaies co-founded Proteolix in 2003. In 2011, he cofounded Cleave Biosciences. Deshaies holds a bachelor's degree in biochemistry from Cornell University and a Ph.D. in biochemistry from the University of California, Berkeley. He is also a member of the National Academy of Sciences, and American Academy of Arts and Sciences.

Carlos Garner, PhD

Dr. Garner joined Eli Lilly and Company in 1997 as a senior scientist where he led a laboratory investigating the drug metabolism, pharmacokinetics and pharmacodynamics of new chemical entities in animal models and human. His work in these areas supported the advancement of many innovative molecules into human testing, late clinical development, and the commercialization of innovative new medicines treating schizophrenia and cancer. Dr. Garner subsequently served as senior director of project management and research strategy overseeing the development of more than 50 programs in discovery and development and providing portfolio strategy and management to Lilly Research Laboratories.

Dr. Garner move into regulatory sciences in 2011 where he led the North American regulatory affairs support of Lilly’s Biomedicines development and product portfolio across neuroscience, musculoskeletal, urology, men's health, cardiovascular, and immunology diseases, where his team brought a number of NMEs and NBE to market and supported the broad portfolio of marketed products. Dr. Garner currently leads the broader regulatory function for Eli Lilly and Company supporting discovery, medical devices, all human health business units, and global manufacturing. Dr. Garner has published numerous scientific articles on his research and in health policy and has been invited to provide national and international lectures on his research, drug discovery, drug development and regulatory sciences.

Kathleen Giacomini, PhD

Kathleen Giacomini, a professor at the University of California, San Francisco, is a leader in the field of membrane transporters with a focus on genetic polymorphisms. She cloned, characterized and discovered the endogenous role of the human xenobiotic transporter, OCT1 (SLC22A1), and recently de-orphaned SLC22A24 and SLC22A15, discovering physiologic and pharmacologic substrates of both transporters. Together with others, she co-founded the International Transporter Consortium, which has published highly impactful papers informing regulatory policy, and the Pharmacogenomics Global Research Network, an independent scientific society focused on research in pharmacogenomics. She is the Co-Principal Investigator of the UCSF-Stanford Center of Excellence in Regulatory Sciences and Innovation, funded by the Food and Drug Administration. She has received numerous awards including an honorary doctorate degree from Uppsala University, and is an elected member of the National Academy of Medicine.
Gary H. Gibbons, MD

Gary H. Gibbons, MD, is Director of the National Heart, Lung, and Blood Institute (NHLBI) at the National Institutes of Health (NIH), where he oversees the third largest institute at the NIH, with an annual budget of approximately $3 billion and a staff of nearly 2,100 federal employees, contractors, and volunteers. NHLBI provides global leadership for research, training, and education programs to promote the prevention and treatment of heart, lung, and blood diseases and enhance the health of all individuals so that they can live longer and more fulfilling lives. Since being named Director of the NHLBI, Dr. Gibbons has enhanced the NHLBI investment in fundamental discovery science, steadily increasing the payline and number of awards for established and early stage investigators. His commitment to nurturing the next generation of scientists is manifest in expanded funding for career development and loan repayment awards as well as initiatives to facilitate the transition to independent research awards. Dr. Gibbons has made many scientific contributions in the fields of vascular biology, genomic medicine, and the pathogenesis of vascular diseases. His research focuses on investigating the relationships between clinical phenotypes, behavior, molecular interactions, and social determinants on gene expression and their contribution to cardiovascular disease. Dr. Gibbons earned his undergraduate degree from Princeton University in Princeton, NJ, and graduated magna cum laude from Harvard Medical School in Boston. He completed his residency and cardiology fellowship at the Harvard-affiliated Brigham and Women's Hospital in Boston. Dr. Gibbons has been a faculty member at Stanford University, Harvard Medical School, and Morehouse School of Medicine in 1999, where he served as the founding director of its Cardiovascular Research Institute.

Christopher Gibson, PhD

Chris Gibson, PhD, is the Co-Founder and CEO of Recursion (NASDAQ:RXRX), a clinical-stage pharmatech company leveraging the latest in automation and artificial intelligence to map and navigate biology and chemistry to discover and develop new medicines at scale. He developed the technology and approach that seeded Recursion as part of his MD/PhD work in the lab of Co-Founder Dr. Dean Li (currently President of Merck Research Labs) while at the University of Utah. After completing his PhD, he left medical school to build Recursion into the rapidly growing company it is today. Dr. Gibson is a graduate of Rice University with degrees in bioengineering and management. He also serves on the Board of BioUtah and is the Chair of BioHive, the public-private partnership driving expansion of Utah’s life-science ecosystem. Dr. Gibson is also active as an advisor and mentor, both formally and informally, of many young biotech founders.

David E. Goel

David Goel is Co-founder and Managing General Partner of Matrix Capital Management, a $10 billion investment firm focused on technology and the life sciences. Mr. Goel is responsible for the firm’s day-to-day management. Prior to forming Matrix in 1999, he was a Member and Technology Research Analyst at Tiger Management. Previously, Mr. Goel was an Associate at General Atlantic Partners and an Investment Banking Analyst at Morgan Stanley. He is a member of the Harvard Medical School Board of Fellows, the Board of Trustees of the American Repertory Theater (A.R.T.) at Harvard University, the Harvard Quantum Initiative (H.Q.I.) Founders Group, the Harvard Corporation Committee on Finance, the Advisory Council of Harvard Kennedy School’s Mossavar-Rahmani Center for Business and Government, the Harvard Faculty of Arts and Sciences (F.A.S.) Boston Major Gifts Committee, and Assistant Treasurer of the Board of Trustees of the Winsor School. He is a Director of nference, Inc., Anumana, Inc., Pramana, Inc., AltpPep Corporation, and Bento Dental. Mr. Goel is a magna cum laude graduate of Harvard University and a cum laude graduate of Phillips Exeter Academy.
Aida Habtezion, MD, MSc, FRCPC

As Chief Medical Officer of Pfizer, Aida Habtezion leads Pfizer’s Worldwide Medical & Safety organization responsible for ensuring that patients, physicians, and regulatory agencies are provided with information on the safe and appropriate use of Pfizer medications. Prior to joining Pfizer, Dr. Habtezion was a practicing physician and scientist at Stanford University’s School of Medicine, Division of Gastroenterology and Hepatology. She led a large translation research lab funded by multiple NIH, DOD, and foundation grants focused on understanding disease mechanisms and identifying potential immune-based therapeutic targets for pancreatic and intestinal inflammatory diseases and their long term complications such as cancer. Her research also included understanding the effect of environmental factors such as cigarette smoke and interaction of immune-enteric nervous system in GI motility disorders. She also served as an Associate Dean for Academic Affairs at Stanford. Dr. Habtezion served in several national and international study sections, including six years in NIH study section, American Gastroenterological Association (AGA) Institute Research Awards and AGA Research Policy Committee. Dr. Habtezion is the recipient of numerous awards and recognitions including: the Robert Wood Johnson Harold Amos Medical Faculty Development Award, being an elected member of the American Society for Clinical Investigation (ASCI), the Association of American Physicians (AAP) and named the 2020 Allen Distinguished Investigator. She currently serves in The New York Academy of Sciences Board of Governors, as Executive Board member for the International Science Reserve, and is the American Pancreas Association (APA) President. Dr. Habtezion is a tenured and endowed Professor of Medicine, currently on a leave of absence from Stanford University. Dr. Habtezion obtained her Bachelor of Science in Chemistry from the University of Alberta and Master of Science in Nutritional Sciences from the University of Guelph. She completed her medical degree from McMaster University. Dr. Habtezion completed her Internal Medicine residency at the University of Western Ontario and Gastroenterology & Hepatology clinical fellowship at the University of Toronto in Canada. Following her clinical fellowship training, she obtained postdoctoral research training in Immunology at Stanford University.

Sandra Horning, MD

Sandra J. Horning, MD currently serves on the Board of Directors of Moderna, Gilead Sciences, Olema Oncology, and EQRx, for which she is also a co-founder. Dr. Horning was Chief Medical Officer and Head of Global Product Development for Roche/Genentech from 2014 until her retirement in 2019. During her tenure, she oversaw the successful development of 15 new molecular entities (NMEs), numerous new indications of marketed products, and 28 FDA Breakthrough Designations in oncology, hematology, neuroscience, ophthalmology, immunology and infectious disease. The Healthcare Businesswomen’s Association named Dr. Horning 2020-21 Woman of the Year. She was a practicing oncologist, investigator and tenured professor at Stanford University School of Medicine for 25 years, where she remains a professor of medicine emerita.
Karin Immergluck, PhD
Dr. Karin Immergluck is the Executive Director of the Office of Technology Licensing (OTL) at Stanford University where she leads a large, internationally renowned team of technology development, licensing and industry contracting professionals. The Stanford OTL handles inventions that come out of Stanford’s research facilities, evaluating their licensing potential and fostering partnerships to make use of that research. Dr. Immergluck is leading several new initiatives within the OTL to increase faculty and investor engagement, and to ensure that the OTL continues to be an active facilitator and promoter of Stanford’s highly successful entrepreneurial ecosystem, which has led to the founding of over 40,000 companies.

Prior to joining Stanford, Dr. Immergluck worked for three years at the UC Office of the President and then for 14 years at UCSF, where she eventually led the Office of Technology Management as Executive Director for five years. Under her leadership, UCSF became a pioneering national leader in digital health licensing and collaboration, faculty were more actively engaged resulting in a 25% increase in invention disclosures per $100M in research funding, and overall licensing productivity was increased by nearly 40%. She also taught several IP-related classes and workshops at UCSF. Karin received her M.S. equivalent in Biochemistry and her Ph.D. in Developmental Molecular Genetics from the University of Zurich in Switzerland. She conducted her doctoral research at UCSF under the dual tutelage of Nobel Laureate and former Chancellor Dr. J. Michael Bishop, and Professor and former President of the Federal Institute of Technology and former Professor of University of Zurich, Dr. Ernst Hafen.

Joe Jimenez, MBA
Joe Jimenez is Co-Founder and Managing Partner at Aditum Bio, a biotech venture firm. From 2010 to 2018, Mr. Jimenez held the position of Chief Executive Officer (CEO) of Novartis, one of the world’s leading pharmaceutical companies. Under his leadership, Novartis developed one of the largest pipelines of self-originated drugs in the industry, driven by a strong commitment to R&D. Mr. Jimenez is currently a member of the Board of Directors of General Motors Company, The Procter & Gamble Company, Century Therapeutics, and Graphite Bio. Additionally, he served on the Board of Directors of Colgate-Palmolive Company from 2009 to 2015, and of AstraZeneca PLC, from 2002 to 2007. He graduated in 1982 with a bachelor’s degree from Stanford University and in 1984 with a Master of Business Administration from the University of California, Berkeley.

Peter Kim, PhD
Peter S. Kim is the Virginia & D.K. Ludwig Professor of Biochemistry at Stanford University School of Medicine and an Institute Scholar of Stanford ChEM-H. He is also the Lead Investigator of the Infectious Disease Initiative at the Chan Zuckerberg Biohub. He was President of Merck Research Laboratories from 2003–2013 and oversaw development of more than 20 new medicines and vaccines, including JANUVIA, GARDASIL, ISENTRESS, ZOSTAVAX, and KEYTRUDA. Earlier, he was Professor of Biology at MIT, Member of the Whitehead Institute and an HHMI Investigator. He is known for discovering a salient component of how proteins cause viral membranes to fuse with cells and has pioneered efforts to create an AIDS vaccine based on inhibiting the HIV-1 membrane-fusion process. He is a member of the National Academy of Sciences, the National Academy of Medicine and the National Academy of Engineering.
**Daphne Koller, PhD**

Daphne Koller is CEO and Founder of insitro, a machine-learning enabled drug discovery company. Daphne is also co-founder of Engageli, was the Rajeev Motwani Professor of Computer Science at Stanford University, where she served on the faculty for 18 years, the co-CEO and President of Coursera, and the Chief Computing Officer of Calico, an Alphabet company in the healthcare space. She is the author of over 200 refereed publications appearing in venues such as Science, Cell, and Nature Genetics. Daphne was recognized as one of TIME Magazine’s 100 most influential people in 2012. She received the MacArthur Foundation Fellowship in 2004 and the ACM Prize in Computing in 2008. She was inducted into the National Academy of Engineering in 2011 and elected a fellow of the American Association for Artificial Intelligence in 2004, the American Academy of Arts and Sciences in 2014, and the International Society of Computational Biology in 2017.

---

**Dean Y. Li, MD, PhD**

Dean Li serves as executive vice president and president of Merck Research Laboratories. He leads the company’s worldwide human vaccines and therapeutics research and development organization. Since joining Merck in 2017 Dean has held leadership roles in the Translational Medicine and Discovery functions and was appointed to President, Merck Research Laboratories in January 2021. Prior to joining Merck, Dean held positions of increasing responsibility in translational medical research at the University of Utah. Most recently he served as the H.A. & Edna Benning Professor of Medicine and Cardiology, chief scientific officer, associate vice president and vice dean at the University of Utah Health System. From 2015 to 2016, he also served as interim CEO of Associated Regional University Pathologists, one of the United States’ largest clinical reference laboratories. During his tenure at the University of Utah, he co-founded several biotechnology companies based upon research conducted in his laboratory, including Recursion Pharmaceuticals, Hydra Biosciences and NavigenPharmaceuticals. Dean received his Bachelor’s degree in Chemistry from the University of Chicago and his graduate and clinical training at Washington University School of Medicine in St. Louis. Dean is a board-certified cardiologist,a member of the American Society for Clinical Investigation and the Association of American Physicians.

---

**Jonathan MacQuitty, PhD**

Jonathan joined Lightspeed in 2016 with over three decades of operating and investing experience in healthcare and life sciences. Jonathan has been instrumental in life science investing for Lightspeed including D2G Oncology, Forty Seven (acquired by Gilead for $4.9B), Orca Bio, Personalis (NASDAQ: PSNL) and Teneobio (acquired by Amgen for up to $2.5B). Jonathan is currently serving as CEO of D2G Oncology, a biotechnology company spun out of Stanford focused on using AI & data driven approaches for translational oncology. He is also serving as Chairman of the Board at Personalis, a cancer genomics company providing advanced molecular data for developing and using novel cancer therapies. Previously Jonathan had served as Founding CEO of Forty Seven, an immuno-oncology company also spun out of Stanford. Prior to Lightspeed, Jonathan served as a partner and head of the West Coast office of Abingworth, a UK based venture capital firm focusing on life sciences. He was also founding CEO of GenPharm International, a Bay Area biotech company specializing in human sequence antibody platforms. Jonathan holds a PhD in Chemistry from the University of Sussex, an MBA from the Stanford Graduate School of Business, and a BA and MA in Chemistry from Oxford University.
Mathai Mammen, MD, PhD

As Executive Vice President, Pharmaceuticals, R&D, Johnson & Johnson (J&J), Mathai’s mission is to focus the energy of the best research and development teams in the world at the intersection of unmet medical need and breakthroughs in science and technology to make medicines with unequivocal benefit for patients worldwide. His team works across a wide range of therapeutic areas and biological pathways to deliver that impact, including: Oncology, Cardiovascular, Metabolic and Retinal Disease, Pulmonary Hypertension, Immunology, Neuroscience, and Infectious Disease and Vaccines.

Mathai is redefining how drugs are discovered and developed, investing deeply in Data Science throughout every aspect of R&D and in immunology across all disease areas. He is also strongly committed to improving access to make medicines and vaccines for all parts of the globe.

Since joining Janssen in June 2017, Mathai built on an already strong foundation to create a truly world-class portfolio, and under his leadership, the organization has advanced seven new FDA-approved prescription medicines and 30 additional approvals for expanded indications or new product formulations to benefit hundreds of millions of patients. Agnostic to the source of innovation, Janssen R&D has also executed more than 40 acquisitions and licenses, and more than 350 strategic partnerships and collaborations to advance its industry-leading portfolios.

Mathai is an inclusive leader, passionate about talent development, and a champion of diversity. He is the executive sponsor of J&J’s Data Science Council, and his patient-first approach has helped fuel Janssen to be one of the largest pharmaceutical companies in the world.

Prior to joining Janssen, Mathai held senior leadership positions at Merck Research Laboratories. He previously led R&D at Theravance, a company he co-founded in the San Francisco Bay Area, which created 31 development candidates and five approved products. Mathai and the team later created Innoviva, a second successful publicly traded company focused on royalty management.

Mathai has more than 150 peer-reviewed publications and patents, and serves on various boards and advisory committees, including 10x Genomics, MIT Abdul Latif Jameel Clinic for Machine Learning in Health, Institute for Medical Engineering and Science and MIT, President’s Advisory Committee for Dalhousie University, and the Vagelos Life Science Management Program at the University of Pennsylvania. He received his M.D. from Harvard Medical School/Massachusetts Institute of Technology (HST program) and his Ph.D. in Chemistry from Harvard University Department of Chemistry, working with George Whitesides. He received his BSc in Chemistry and Biochemistry from Dalhousie University in Halifax, Nova Scotia.

Peter Marks, MD, PhD

Peter Marks received his graduate degree in cell and molecular biology and his medical degree at New York University and completed Internal Medicine residency and Hematology/Medical Oncology training at Brigham and Women’s Hospital in Boston. He has worked in academic settings teaching and caring for patients and in industry on drug development. He joined the FDA in 2012 as Deputy Center Director for CBER and became Center Director in January 2016.
Michelle McMurry-Heath, MD, PhD

BIO represents nearly 1,000 life sciences companies and organizations from 30 countries. The organization’s mission is to support companies that discover and deploy scientific breakthroughs that improve human health, environmental stewardship, and sustainable agriculture. Since assuming leadership of BIO on June 1, 2020, Dr. McMurry-Heath has positioned BIO as a leading champion of scientific innovation and the bio-revolution, which aims to use technological breakthroughs to cure patients, protect our climate, and nourish humanity. A common thread throughout McMurry-Heath’s career has been her focus on broadening access to scientific progress so more patients from diverse backgrounds can benefit from cutting-edge advancements. She calls the distribution of scientific progress “the social justice issue of our age.” Before coming to BIO, Dr. McMurry-Heath worked at Johnson & Johnson, where she served as Global Head of Evidence Generation for Medical Device Companies and then Vice President of Global External Innovation and Global Leader for Regulatory Sciences. Prior to her time at J&J, Dr. McMurry-Heath was a key science policy leader in government, including serving as the associate science director of the FDA’s Center for Devices and Radiological Health. McMurry-Heath was also the founding director of the Aspen Institute’s Health, Biomedical Science, and Society Policy Program. McMurry-Heath received her MD/PhD from Duke’s Medical Scientist Training Program, becoming the first African American to graduate from the prestigious program.

Maria Millan, MD

Dr. Maria Millan is a physician-scientist who has devoted her career to treating and developing innovative solutions for children and adults with debilitating and life-threatening conditions. After obtaining her MD, she completed her surgical training and post-doctoral research at Harvard Medical School – Beth Israel Deaconess Medical Center. After a transplant surgery fellowship at Stanford, she began her academic career with a busy pediatric and adult transplant surgery practice focused on technical advancements and optimization of patient outcomes. In parallel, she was promoted to Associate Professor and the Director of the Pediatric Organ Transplant Program at Stanford. She also served on the Medical School’s Faculty Senate and the Lucile Packard Children’s Hospital operations committee. In 2006, Maria joined StemCells, Inc., and joined the California Institute for Regenerative Medicine in 2012 where she led the formation of the Alpha Stem Cell Clinics Network. This clinical network successfully supports over 45 clinical trials and was recently expanded to include 5 programs composed of 7 medical centers and affiliated hospitals. In July 2017, Dr. Millan took on the role as President and CEO of CIRM. Under her leadership, CIRM continues to drive the mission of accelerating stem treatments to patients with unmet medical needs.
Vern Norviel, JD

Vern Norviel is a partner at Wilson Sonsini Goodrich & Rosati and a senior practitioner in the firm’s patents and innovations counseling practice. Vern has three decades of experience formulating successful strategies for life science companies and helping them develop IP programs. He represents a wide variety of companies, as well as venture capital firms, in areas such as therapeutics, diagnostics, nanotechnology, genomics, proteomics, and personalized medicine. In fact, Vern’s interest in the field of personalized medicine prompted him to become the first attorney to have had his or her entire genome sequenced and made available in a public database. Before joining the firm in 2003, Vern was the general counsel and corporate secretary of Perlegen Sciences, Inc., a start-up biotechnology company that scans the entire human genome for important therapeutic and diagnostic products. Previously, as senior vice president and general counsel, he was an early employee of Affymetrix, the biotechnology company that pioneered and developed DNA chip technology. He also had been a partner at Townsend and Townsend and Crew in Palo Alto. During his career, Vern has authored or prosecuted dozens of patents that have been litigated in the U.S. and abroad; and has overseen intellectual property lawsuits throughout the world. Vern previously served as a member of Wilson Sonsini’s board of directors and currently serves on the board of the Wilson Sonsini Foundation. In addition, he is a lecturer in biotechnology law at UC Berkeley School of Law.
Merdad Parsey, MD, PhD

Merdad Parsey, MD, PhD is Gilead Sciences’ chief medical officer, responsible for overseeing the company’s global clinical development and medical affairs organizations. With an unrelenting commitment to create a healthier world for all people, Merdad supervises all clinical trials and development operations. Together with the leadership team, he works to advance clinical development strategies and programs with the goal of changing the trajectory of disease, and transforming care for the patients of today and tomorrow. Merdad joined Gilead in 2019, after serving as senior vice president of Early Clinical Development at Genentech, where he led clinical development for areas including inflammation, oncology and infectious diseases. Prior to Genentech, Merdad served as President and CEO of 3-V Biosciences (now Sagimet BioSciences), held development roles at Sepracor, Regeneron and Merck, Inc. and was Assistant Professor of Medicine and Director of Critical Care Medicine at the New York University School of Medicine. He completed his MD and Ph.D. at the University of Maryland, Baltimore, his residency in Internal Medicine at Stanford University and his fellowship in Pulmonary and Critical Care Medicine at the University of Colorado. Merdad currently serves on the Board of Directors for Sagimet BioSciences.

Andrew Plump, MD, PhD

Andrew Plump, MD, PhD, is the president of Research & Development at Takeda Pharmaceutical Company Limited and serves as a member of the company’s board of directors. His career spans nearly 30 years in the pharmaceutical industry and academia and his experience encompasses early research through regulatory approval and patient access.

Dr. Plump oversees Takeda’s global R&D organization of more than 5,000 employees. Early in his tenure he orchestrated a multi-year strategic and cultural transformation that has resulted in a renewed focus on innovation, streamlined global footprint, prioritized therapeutic areas of focus, a rich network of partnerships and a modality-diverse portfolio of newly approved and promising late-stage development experimental therapies. He also championed efforts to build an exciting and sustainable early development and research pipeline, founded on strong translational science as well as platform capabilities in cell therapy, gene therapy and data sciences. Over the last several years, Dr. Plump has substantially increased the company’s investment in research and partnerships and the launch and growth of medicines that provide meaningful benefit to society.

Dr. Plump has been recognized for his contributions to the healthcare industry, education and the arts. He serves on several not-for-profit boards including the board of directors of the PhRMA Foundation, the Sarnoff Cardiovascular Research Foundation and the Biomedical Science Careers Program. He also serves in advisory board positions at BioCentury and the Boston Symphony Orchestra.

Prior to Takeda, Dr. Plump served as head of Research & Translational Medicine, deputy to the president of R&D at Sanofi, based in Paris, France. Prior to Sanofi, Dr. Plump served as worldwide cardiovascular (CV) research head at Merck.

Dr. Plump received his M.D. from the University of California, San Francisco (UCSF), his Ph.D. in cardiovascular genetics with Dr. Jan Breslow at Rockefeller University and his B.S. from the Massachusetts Institute of Technology (MIT). He completed a residency in internal medicine and a fellowship in medical genetics at UCSF. Following his clinical training, Dr. Plump trained as a Howard Hughes and Stanley J. Sarnoff postdoctoral fellow with Dr. Marc Tessier-Lavigne at UCSF, concurrently assuming faculty responsibilities as an adjunct clinical instructor in the department of medical genetics.

Dr. Plump and his wife, Suzanne Driscoll Plump, PhD, reside in Chestnut Hill, MA, with their three children.
Aviv Regev, PhD

As Executive Vice President, Genentech Research and Early Development (gRED), Aviv Regev is responsible for the management of all aspects of Genentech’s drug discovery and drug development activities. She is a member of the Genentech Executive Committee and the expanded Corporate Executive Committee for Roche. Prior to Genentech, Regev served as Chair of the Faculty, Core Institute Member, founding director of the Klarman Cell Observatory, and member of the Executive Leadership Team of the Broad Institute of MIT and Harvard, as well as Professor of Biology at MIT and Investigator at the Howard Hughes Medical Institute. She is a founding co-chair of the Human Cell Atlas. Regev has served on multiple corporate advisory, scientific advisory, and journal editorial boards, including the advisory committee to the National Human Genome Research Institute at the National Institutes of Health. Regev is a leader in deciphering molecular circuits that govern cells, tissues and organs in health and their malfunction in disease. Her lab has pioneered foundational experimental and computational methods in single-cell genomics, working toward greater understanding of the function of cells and tissues in health and disease, including autoimmune disease, inflammation and cancer. She is a member of the National Academy of Sciences and National Academy of Medicine, and she is also a Fellow of the International Society of Computational Biology. Regev has a PhD in computational biology and a Master of Science from Tel Aviv University.

Madhuri Roy, JD, PhD

Dr. Madhuri (Mani) Roy focuses her practice in developing and implementing comprehensive patent portfolio strategies for biotechnology, pharmaceutical and chemical companies. This work includes patent preparation and prosecution, strategic patent counseling and intellectual property due diligence. She also has carried out investor-side and company-side due diligences, freedom-to-operate analyses, patentability analyses and prelitigation work involving questions of validity and non-infringement. Mani brings 10+ years of integrative biotechnology experience to her practice. She has industry experience in mid-size and large biotech companies in the areas of discovery, target validation, screening and in vivo pharmacology. She has also conducted academic research in the molecular and cellular aspects of neurodegenerative and neuropsychiatric diseases. She has authored numerous scientific publications. Prior to joining Cooley, Mani was an associate at Morrison & Foerster and prior to law school, she worked as a patent agent at Wilson Sonsini Goodrich & Rosati. In these previous roles, she specialized in strategic patent counseling, prosecution and pre-litigation analyses for biotechnology clients. Mani has an active pro bono practice focusing on providing legal services for those in need through the Pro Bono Project’s Lawyers in the Library program and working on Immigration and Naturalization matters. Her doctoral research at Stanford University focused on the molecular and cellular aspects of gene therapy for the central nervous system.
Alfred Sandrock, MD, PhD

Dr. Sandrock has been CEO of Voyager and a Board member since March of 2022. Dr. Sandrock joined Voyager following a 23-year career at Biogen where he identified and developed novel therapies for a variety of serious diseases. While at Biogen, Dr. Sandrock served in positions of increasing responsibility, culminating in his service as Executive Vice President, Research and Development. He also served as Chief Medical Officer and held a seat on the Biogen Executive Committee. Over the course of his tenure, he led the discovery and development, and regulatory approval of several medicines for multiple sclerosis, spinal muscular atrophy, and Alzheimer’s Disease. Dr. Sandrock earned a B.A. in human biology from Stanford University, an M.D. from Harvard Medical School, and a Ph.D. in neurobiology from Harvard University. He completed an internship in medicine, a residency and chief residency in neurology, and a clinical fellowship in Neuromuscular Disease and Clinical Neurophysiology at Massachusetts General Hospital. He was Assistant Professor in Neurology at Harvard Medical School and an Associate in Neurology at Massachusetts General Hospital prior to joining Biogen.

Randy Schekman, PhD

Dr. Randy Schekman is a Professor in the Department of Molecular and Cell Biology, University of California, Berkeley, and an Investigator of the Howard Hughes Medical Institute. He studied the enzymology of DNA replication as a graduate student with Arthur Kornberg at Stanford University. His current interest in cellular membranes developed during a postdoctoral period with S. J. Singer at the UC Diego. Among his awards are the Gairdner International Award, the Albert Lasker Award in Basic Medical Research and the Nobel Prize in Physiology or Medicine, which he shared with James Rothman and Thomas Südhof. Beginning in 2018, Schekman has served as the Scientific Director of “Aligning Science Across Parkinson’s Disease” a major philanthropic effort organized along with The Michael J. Fox Foundation to identify molecular and cellular mechanisms in the initiation and progression of Parkinson’s Disease (https://parkinsonsroadmap.org). Schekman’s laboratory investigates the mechanism of vesicular traffic in the secretory pathway in eukaryotic cells. Currently the lab investigates the mechanism of biogenesis of extracellular vesicles including how small RNAs are sorted for secretion in exosomes and the means by which these vesicles are internalized and function in target cells.

Marc Tessier-Lavigne, PhD

Pioneering neuroscientist Marc Tessier-Lavigne became Stanford University’s 11th president on September 1, 2016. He returned to Stanford after serving as President of The Rockefeller University, a graduate biomedical research university in New York City. From 2001 to 2005, he was a Professor of biological sciences at Stanford, where he held the Susan B. Ford Professorship in the Humanities and Sciences. He has also held faculty positions at the University of California, San Francisco, and executive positions, including Chief Scientific Officer at Genentech.
James Zou, PhD

Dr. James Zou is an Assistant Professor of Biomedical Data Science and, by courtesy, of Computer Science and Electrical Engineering at Stanford University. He works on making machine learning more reliable, human-compatible and statistically rigorous, and is especially interested in applications in human disease and health. Dr. Zou received his Ph.D from Harvard in 2014, and was at one time a member of Microsoft Research, a Gates Scholar at Cambridge and a Simons fellow at U.C. Berkeley. He joined Stanford in 2016. Dr. Zou develops novel machine and deep learning algorithms that have a strong statistical guarantee, and several of his methods are currently being used by biotech companies. Dr. Zou has received several awards, including Google Faculty Award, a Tencent AI award, and is a Chan-Zuckerberg Investigator.
Organizing Committee

**Amanda Chase, PhD**
Associate Director of Strategic Research Development
Cardiovascular Institute
Stanford University School of Medicine

**Sanjay V. Malhotra, PhD**
Professor & Endowed Chair in Cancer Research; Department of Cell Development & Cancer Biology
Director, Center for Experimental Therapeutics; Knight Cancer Institute
Oregon Health & Science University

**Mark Mercola, PhD**
Professor of Medicine (Cardiovascular)
Stanford University School of Medicine

**Joseph C. Wu MD, PhD**
Director, Stanford Cardiovascular Institute; Simon H. Stertzer, MD, Professor of Medicine and Radiology
Stanford University School of Medicine

**Kuldev Singh, MD**
Professor of Ophthalmology
Stanford University School of Medicine

**Francesca Tongco, MS-HCA**
SDDS Program Manager
Cardiovascular Institute, Stanford University School of Medicine

**David Preston, MA, MBA**
SDDS Staff Support
Cardiovascular Institute, Stanford University School of Medicine

Administrative Support
Thank you to our sponsors!

Platinum

Abbvie  
Alexandria  
Biomarin  
CIRM  
Cytokinetics  
Genentech  
Gilead  
Stanford  
Stanford Health Care

Gold

AMI USC  
AMGEN  
Arctoris  
Merck  
Novartis  
Servier  
Stanford Cancer Institute  
Wilson Sonsini
Thank you to our sponsors!

**Silver**

- AlwaysRAISE
- astellas
- Cooley
- Greenstone Biosciences
- Janssen
- Pfizer
- ThermoFisher Scientific
- Vala Sciences
- (w)Catalyst

**Media Sponsors**

- Biocom California
- CLSA (California Life Sciences Association)
- Oregon Health & Science University

**KEYSTONE SYMPOSIA**